20-F: Black Titan Completes Merger, Reports TalenTec Growth
Annual Report
Black Titan Corporation finalized its merger with Titan Pharmaceuticals and TalenTec Sdn. Bhd., with TalenTec reporting significant revenue and net income growth for fiscal year 2025.
Summary
- Black Titan Corporation completed its merger with Titan Pharmaceuticals Inc. (TTNP) and TalenTec Sdn. Bhd. on October 1, 2025, with Black Titan's ordinary shares commencing trading on Nasdaq under the ticker BTTC on October 2, 2025.
- TalenTec, the accounting acquirer in the reverse recapitalization, reported total revenues of $2,683,126 for the year ended July 31, 2025, a 26.3% increase from $2,124,496 in fiscal year 2024.
- Net income for TalenTec increased to $209,911 in fiscal year 2025, up from $153,227 in fiscal year 2024.
- TalenTec's gross profit rose to $884,928 in fiscal year 2025 from $686,835 in fiscal year 2024.
- Cash provided by TalenTec's operating activities improved significantly to $394,218 in fiscal year 2025 from $191,554 in fiscal year 2024.
- Black Titan incurred a net loss of $163,173 for the year ended July 31, 2025, and had a working capital deficit of $167,120, raising substantial doubt about its ability to continue as a going concern prior to the merger.
- The company plans to expand its HCM solutions business regionally to Indonesia and the Philippines and is participating in the development of a new SaaS HCM application for the hospitality industry.
- A private placement (PIPE) for up to $6,000,000 in Series A convertible preferred shares was amended, with $5,500,000 drawn down on October 1, 2025.
- The company announced plans on October 6, 2025, to seek long-term strategic crypto initiatives, including direct coin acquisitions, mining, and fintech-related M&A.
Sentiment
Score: 7
Explanation: The company has completed a significant merger, and its core operating subsidiary (TalenTec) shows strong revenue and net income growth, along with positive cash flow from operations. Strategic plans for regional expansion and new product development align with industry trends. However, the parent company's initial financial state (losses, working capital deficit) and numerous operational and market risks, including dependence on key customers and third-party vendors, temper the overall positive outlook. The new crypto strategy introduces additional, unquantified risk and opportunity.
Positives
- TalenTec's total revenues increased by 26.3% to $2,683,126 in fiscal year 2025.
- TalenTec's net income grew by 37.0% to $209,911 in fiscal year 2025.
- Cash provided by TalenTec's operating activities increased by 105.8% to $394,218 in fiscal year 2025.
- TalenTec achieved a 100% subscription renewal rate for existing customers in both fiscal years 2024 and 2025.
- The company has a strong, long-term client base, including a regulatory authority in Malaysia for over 25 years.
- The company is expanding its product offerings to include cloud-based solutions and developing a new SaaS HCM application for the hospitality industry.
- The Human Capital Management (HCM) software market in APAC is projected to grow at a CAGR of 15.02% to $18.18 billion by 2030, providing a favorable market for the company's growth strategies.
- The company successfully secured a $5,500,000 drawdown from a Series A convertible preferred shares PIPE.
Negatives
- Black Titan Corporation incurred a net loss of $163,173 for the year ended July 31, 2025, and had a working capital deficit of $167,120, raising substantial doubt about its ability to continue as a going concern prior to the merger.
- TalenTec had projected working capital deficits for fiscal years 2024 through 2026, with deficits of $387,000, $646,000, and $976,000, respectively, prior to an $800,000 equity investment.
- The company depends on a few customers for a significant part of its revenue, with three customers accounting for approximately 34% of total revenue in fiscal year 2025.
- Most of the company's customer contracts are short-term, requiring continuous securing of new contracts to maintain business.
- The company's long-term success depends on its ability to expand sales outside Malaysia, which is subject to international operational risks and lack of experience in new markets like the Philippines.
- TalenTec's management team has limited experience managing a public company, which could strain resources and divert attention.
Risks
- Dependence on licenses, reseller contracts, and distribution agreements with third-party software vendors (e.g., Oracle, Dayforce, Humanica, Microimage); changes in terms or termination could materially affect financial performance.
- Intense competition from other HCM solutions providers and vendors, including direct competition from its own software vendors, potentially leading to reduced sales, margins, or market acceptance.
- Reliance on a few key customers for a significant portion of revenue; loss of these customers would have a significant adverse impact.
- Target market is limited to large organizations with substantial human resources budgets due to the high cost of HCM solutions.
- Project-based and contract-based nature of business and timing of delivery may lead to fluctuations in revenue, profit, and operating cash flow.
- Exposure to credit risk and default payment by customers, potentially leading to impairment losses on trade receivables or bad debts.
- Borrowing risks and restrictive covenants in credit facilities, including limitations on dividend distributions and potential for default.
- Exposure to foreign exchange transaction risks, which may impact profitability due to fluctuations in MYR or SGD against other transacted currencies.
- HCM solution project deliverables are exposed to unexpected delays or interruptions caused by operational factors, accidents, and natural disasters beyond control.
- Customers may claim liquidated damages for delays or failures in providing services, potentially increasing operating costs and adversely affecting financial performance.
- Success depends on growth in market acceptance of the digitalization of human resources processes; reluctance of companies to switch to new solutions could hinder growth.
- Inability to rapidly grow its sales force could prevent anticipated business growth.
- Failure to maintain or enhance reputation or brand recognition could harm business.
- Inability to successfully implement business strategies, including regional expansion and new solution development, could adversely affect financial performance.
- Exposure to economic, political, legal, and regulatory environments in countries of operation (Malaysia, Singapore, Indonesia, Philippines, Hong Kong, Taiwan, Australia).
- Inadequate insurance coverage for all potential losses or liabilities.
- Changes in laws and regulations related to the Internet or changes in Internet infrastructure may diminish demand for solutions.
- Volatility in the financial and economic environment could harm business, as demand for services is sensitive to economic activity.
- Financial results may fluctuate due to many factors, some beyond control, including customer acquisition, retention, solution mix, pricing, and seasonal factors.
- Business is subject to numerous legal and regulatory risks, including privacy law, data regulation, antitrust, foreign ownership restrictions, and tax law.
- Third-party HCM solutions are exposed to the risk of security breaches, potentially affecting reputation and leading to costs.
- Privacy concerns, evolving regulation of cloud computing, and cross-border data transfer may reduce adoption of solutions.
- Use of open source software in solutions (Sunfish Workplaze HR) carries risks of non-compliance with license terms, potentially requiring source code release or re-engineering.
- If Black Titan fails to implement and maintain an effective system of internal controls, it may be unable to accurately report results or prevent fraud.
- If Black Titan ceases to qualify as a foreign private issuer, it would incur significant additional legal, accounting, and other expenses.
- As a foreign private issuer, Black Titan is exempt from certain Nasdaq corporate governance standards, potentially offering less protection to investors.
- There is no assurance that Black Titan Ordinary Shares will remain listed on Nasdaq or that the company can comply with continued listing standards.
- A market for Black Titan's securities may not continue, affecting liquidity and price.
- If the Business Combination's benefits do not meet expectations, the market price of securities may decline.
- The IRS may not agree that Black Titan should be treated as a non-U.S. corporation for U.S. federal income tax purposes, leading to substantial U.S. tax liability.
- If Black Titan or any subsidiary were a passive foreign investment company (PFIC) for U.S. federal income tax purposes, U.S. Holders could be subject to adverse U.S. federal income tax consequences.
Future Outlook
The company aims to be a leading human resources consulting group in its markets, expanding its regional presence in Southeast Asia (Indonesia, Philippines, Vietnam), enhancing existing offerings, and increasing sales. It plans to continue adding to its suite of HCM solutions, including participating in the development of a new SaaS HCM application for the hospitality industry. The company also intends to build strong customer relationships to facilitate the transition to hybrid and cloud-based solutions, expecting increased revenue from this shift. Additionally, Black Titan is exploring long-term strategic crypto initiatives, including direct coin acquisitions, mining, and fintech-related mergers and acquisitions.
Management Comments
- Management expects Black Titan to continue relying on related-party support and anticipated Transaction Financing until completion of the Business Combination.
- Management plans to address going concern uncertainty through the Business Combination and continued financial support from its shareholder, who has committed to provide necessary funding.
- Management aims to position the Company not just as a software reseller, but, through long-term relationships, as a strategic partner that enhances human resource capabilities through technology and innovative solutions.
- We believe that our ability to support the different solutions that it sources, with its on-staff consultants, gives the Company a competitive edge that the Company believes other HCM service providers do not offer.
- We are optimistic about available expansion opportunities, given our broad range of products and services tailored to organizations of varying sizes across multiple industries, as many organizations in Southeast Asia region have not yet adopted cloud-based HCM solutions.
- Our management team is expanding services related to digitalization, leading to increased sales and marketing expenses.
Industry Context
The Human Capital Management (HCM) software market in APAC is experiencing steady growth, projected to reach $18.18 billion by 2030 with a 15.02% CAGR, driven by digitalization, cloud adoption, and the increasing use of AI in HR functions. The Malaysian government's support for digitalization and increasing demand for unified HR solutions are key market drivers. The company's strategy to focus on cloud-based solutions and expand regionally aligns with these trends, particularly as 60% of midmarket and large enterprises are expected to invest in cloud-deployed HCM suites by 2025. Competitors like Ramssol, Payroll2U, and Kakitangan.com indicate a fragmented but growing market, with the company differentiating itself through multi-vendor sourcing and extensive consulting expertise.
Comparison to Industry Standards
- The APAC HCM market is estimated to generate $9.03 billion in 2025 and reach $18.18 billion by 2030, growing at a CAGR of 15.02%.
- Malaysia HCM revenue is projected to grow at a 14.15% CAGR to $422.7 million by 2030, and Singapore HCM revenue at a 13.98% CAGR to $354.6 million by 2030.
- Indonesia HCM revenue is expected to grow to $165.5 million (CAGR, 12.85%) by 2030, and Vietnam to $186.8 million (6.5%) by 2033.
- According to the 2023 Gartner Market Guide for Workforce Management Applications, by 2025, 60% of midmarket and large enterprise organizations will have invested in a cloud-deployed HCM suite, which TalenTec is actively pursuing.
- Competitors in Southeast Asia include Ramssol Group Bhd (specializing in Oracle HCM and other digitalization solutions), Payroll2U (payroll outsourcing and SaaS solutions like smartPAY), and Kakitangan.com (HCM platform for small and medium businesses).
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Co-Chief Executive Officer and Director (Black Titan) | N/A | Chay Weei Jye | 2025-09-18 | Appointment following merger and previous role as CEO of TTNP. |
| Co-Chief Executive Officer (Black Titan) | N/A | Shang Ju (Czhang) Lin | 2025-11-10 | Appointment following merger. |
| Chief Financial Officer and Director (Black Titan) | N/A | Brynner Chiam | 2025-08-21 | Appointment following merger and previous roles as sole director and principal executive officer of Black Titan, and acting principal executive/financial officer of TTNP. |
| Independent Director (Black Titan) | N/A | Francisco Osvaldo Flores Garcia | 2025-10-01 | Appointment following merger. |
| Independent Director (Black Titan) | N/A | Firdauz Edmin Bin Mokhtar | 2025-10-01 | Appointment following merger. |
| Independent Director (Black Titan) | N/A | Gabriel Loh | 2025-10-01 | Appointment following merger. |
| Independent Director (Black Titan) | N/A | Avraham Ben-Tzvi | 2025-10-01 | Appointment following merger (previously served on TTNP board). |
| Chief Executive Officer (Titan Pharmaceuticals) | Seow Gim Shen | Brynner Chiam (acting) | 2024-11-06 | Seow Gim Shen resigned for personal reasons. |
| Chief Executive Officer (Titan Pharmaceuticals) | Brynner Chiam (acting) | Chay Weei Jye | 2024-12-02 | Appointment. |
| Chairman of the Board (Titan Pharmaceuticals) | Seow Gim Shen | N/A | 2024-10-24 | Resigned for personal reasons. |
| President and Chief Operating Officer (Titan Pharmaceuticals) | Kate Beebe DeVarney, Ph.D. | N/A | 2024-04-02 | Resignation. |
| Director (Titan Pharmaceuticals) | David Lazar | N/A | 2023-09-13 | Resignation pursuant to Sire Purchase Agreement. |
| Director (Titan Pharmaceuticals) | Peter Chasey | N/A | 2023-09-13 | Resignation pursuant to Sire Purchase Agreement. |
| Director (Titan Pharmaceuticals) | Eric Greenberg | N/A | 2024-04-02 | Resignation. |
| Director (Titan Pharmaceuticals) | Matthew C. McMurdo | N/A | 2024-04-02 | Resignation. |
| Director (Titan Pharmaceuticals) | David Natan | N/A | 2024-04-02 | Resignation. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| New Board Composition | Black Titan's board consists of six directors, with four qualifying as independent under Nasdaq guidelines. This includes Co-CEOs Chay Weei Jye and Shang Ju Lin, CFO Brynner Chiam, and independent directors Francisco Osvaldo Flores Garcia, Firdauz Edmin Bin Mokhtar, Gabriel Loh, and Avraham Ben-Tzvi. | 2025-10-01 | Establishes the governance structure for the newly combined public company, aligning with Nasdaq listing requirements for independence, albeit with exemptions as a foreign private issuer. |
| Audit Committee Establishment | A separately standing audit committee was established, consisting of Firdauz Edmin Bin Mokhtar (chair), Francisco Osvaldo Flores Garcia, and Gabriel Loh. All members are independent and financially literate, with Mr. Mokhtar identified as an audit committee financial expert. | 2025-10-01 | Enhances financial oversight, auditor independence, and compliance with SEC and Nasdaq requirements, crucial for a public company. |
| Nominating and Corporate Governance Committee Establishment | A nominating and corporate governance committee was established, consisting of Francisco Osvaldo Flores Garcia (chair), Avraham Ben-Tzvi, and Firdauz Edmin Bin Mokhtar. All members are independent. | 2025-10-01 | Formalizes the process for director nominations, board evaluation, and the development of corporate governance guidelines, improving board effectiveness and accountability. |
| Compensation Committee Establishment | A compensation committee was established, consisting of Firdauz Edmin Bin Mokhtar and Francisco Osvaldo Flores Garcia (chair). Both members are independent. | 2025-10-01 | Provides independent oversight of executive compensation, incentive plans, and related policies, aligning management incentives with shareholder interests. |
| Code of Ethics Adoption | A code of ethics that applies to all executive officers, directors, and employees was adopted. | N/A | Establishes ethical standards and promotes compliance with laws and regulations, enhancing corporate integrity and reducing legal/reputational risks. |
| Insider Trading Policy Adoption | An insider trading policy was adopted to prevent violations by directors, officers, employees, and related individuals, including blackout periods and pre-clearance requirements. | N/A | Mitigates the risk of insider trading, ensuring fair and transparent trading in company securities and compliance with securities laws. |
| Compensation Recovery Policy Adoption | A Compensation Recovery Policy (clawback policy) was adopted to recover erroneously awarded compensation from Covered Persons in the event of a financial restatement, in accordance with SEC and Nasdaq rules. | N/A | Enhances accountability of executive officers and protects shareholder interests by allowing the company to recover incentive-based compensation tied to inaccurate financial reporting. |
| Foreign Private Issuer Exemptions | The company, as a foreign private issuer, elects to follow Cayman Islands corporate governance practices in lieu of certain Nasdaq standards, such as not requiring a majority of independent directors or shareholder approval for certain share issuances. | 2025-10-01 | Provides flexibility in governance but may offer less protection to shareholders compared to U.S. domestic issuers, as board oversight and shareholder approval mechanisms may differ. |
Legal Proceedings
- Titan Pharmaceuticals was subject to a legal proceeding initiated in 2020 by a former employee alleging wrongful termination, retaliation, emotional distress, negligent supervision, hiring and retention, and slander. Fedson, Inc. assumed all liabilities related to this claim as part of the Asset Purchase Agreement in September 2023.
- The company is not currently a party to any other legal proceedings the outcome of which would individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.
Related Party Transactions
- Black Titan Corporation incurred administrative expenses charged by a related party, amounting to $3,947 for the period from July 11, 2024, to July 31, 2024, and $163,173 for the year ended July 31, 2025.
- As of July 31, 2025, Black Titan had total liabilities of $167,120 and a working capital deficit of $167,120, reflecting additional related-party advances used to fund transaction costs.
- Mr. Choong Choon Hau, a shareholder of Black Titan Corporation, has committed to fund working capital to the combined company.
- TalenTec had transactions with HO SAY SAN (shareholder and director) for borrowings and repayments in fiscal year 2024.
- TalenTec had transactions with CHOO YEOW (shareholder and director) who provided guarantees for bank borrowings.
- The Sire Group Ltd. (controlled by Jeffrey Chung, previously by Mr. Seow, a former significant shareholder of TalenTec) made payments of professional fees on behalf of TalenTec amounting to $355,450 in fiscal year 2024.
- As of July 31, 2025, a balance of $377,317 was payable to The Sire Group Ltd., reclassified from 'amount due to a related party' to 'non-trade creditors'.
- Titan Pharmaceuticals made payments related to legal and consulting fees of approximately $7,538 and $11,138 during the nine months ended September 30, 2025 and 2024, respectively, to a law firm operated by one of its Board members.
- As of September 30, 2025, Titan Pharmaceuticals had a receivable balance of approximately $232,000 from Black Titan, including advances of approximately $170,000 made during the nine months ended September 30, 2025.
- In August 2023, Titan Pharmaceuticals received $500,000 in funding from Choong Choon Hau in exchange for a convertible promissory note, which was converted into 54,132 shares of common stock in March 2024.
Stakeholder Impact
- **Shareholders:** The merger and Nasdaq listing provide liquidity and potential for value appreciation. However, dilution from preferred stock conversions and future capital raises, along with the inherent risks of a public company and the new crypto strategy, could impact share value. The clawback policy enhances accountability.
- **Employees:** The company's growth strategies, including regional expansion and new product development, suggest potential for job creation and career advancement, particularly for sales and technical staff. The focus on retaining skilled consultants is critical.
- **Customers:** The company's commitment to enhancing HCM solutions, expanding product offerings (including cloud-based and AI-integrated solutions), and providing strong technical support aims to improve customer satisfaction and operational efficiency. However, project delays and security breaches could negatively impact customer experience.
- **Suppliers/Vendors:** The company's dependence on third-party software vendors means continued business for them, but changes in terms or termination of agreements could affect both parties. The company's diversification of product sourcing may reduce reliance on any single vendor.
- **Creditors:** The company's working capital position and ability to secure financing (like the PIPE) are important for its ability to meet obligations. The going concern doubt for Black Titan prior to the merger highlights financial risks, though shareholder commitment and the merger proceeds aim to mitigate this.
Next Steps
- Expand operations in Singapore, Indonesia, and extend to the Philippines and Vietnam.
- Continue to add to the suite of HCM solutions, including participating in the development of a new SaaS HCM application for the hospitality industry.
- Roll out the beta version of the new HCM cloud solution in the 2026 second fiscal quarter.
- Continue to build and develop strong relationships with customers, enhance customer retention, and encourage referrals.
- Attract suitable talent regionally and increase sales and marketing activities.
- Explore additional investments to expand the cryptocurrency portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions.
Key Dates
| Date | Description |
|---|---|
| 1990-02-14 | TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) was incorporated in Malaysia. |
| 1993 | TalenTec became one of the first licensees of PeopleSoft Human Resource and Payroll solutions in the Asia Pacific region. |
| 2010-11-22 | TalenTec entered into a credit facility agreement with Alliance Bank Malaysia Berhad. |
| 2018-12-05 | TalenTec entered into a term loan agreement with AmBank (M) Berhad. |
| 2019 | TalenTec became a Channel Partner of Microimage Channel Partner, distributing MiHCM Enterprise. |
| 2021-03-01 | TalenTec entered into a term loan agreement with Alliance Bank Malaysia Berhad. |
| 2022-06 | Titan Pharmaceuticals implemented a plan to reduce expenses and conserve capital. |
| 2022-07-01 | TalenTec entered into a term loan agreement with Alliance Bank. |
| 2023-07 | Titan Pharmaceuticals entered into an asset purchase agreement with Fedson, Inc. for the sale of ProNeura Assets. |
| 2023-07-25 | An investor subscribed for 80,000 ordinary shares of TalenTec for $800,000. |
| 2023-08 | Titan Pharmaceuticals entered into an Amendment and Extension Agreement to the Asset Purchase Agreement with Fedson. |
| 2023-08 | Titan Pharmaceuticals received $500,000 in funding from Choong Choon Hau in exchange for a convertible promissory note. |
| 2023-09-01 | Titan Pharmaceuticals closed on the sale of certain ProNeura assets to Fedson, Inc. |
| 2023-09-13 | Titan Pharmaceuticals entered into a Securities Purchase Agreement with The Sire Group Ltd. for $9.5 million in Series AA Preferred Stock. |
| 2023-09-23 | The $4.5 million promissory note from Sire was fully repaid to Titan Pharmaceuticals. |
| 2023-10-12 | Brynner Chiam and Seow Gim Shen were elected to Titan Pharmaceuticals' Board of Directors, with Seow Gim Shen appointed as Chairman. |
| 2023-12 | The Cash Note from Fedson was paid to Titan Pharmaceuticals. |
| 2024-01-01 | The Escrow Note from Fedson was due and payable to Titan Pharmaceuticals. |
| 2024-01-05 | A leading technology corporation renewed its two-year contract with TalenTec for PeopleSoft support, maintenance, and enhancement services. |
| 2024-01-08 | Titan Pharmaceuticals' Board effected a 1-for-20 reverse stock split. |
| 2024-01 | The Escrow Note from Fedson was paid to Titan Pharmaceuticals. |
| 2024-02 | Titan Pharmaceuticals received funds from the escrow account related to the ProNeura asset sale. |
| 2024-03 | The Hau Promissory Note, along with accrued interest, was converted into 54,132 shares of Titan Pharmaceuticals' common stock. |
| 2024-04-02 | David Lazar, Kate Beebe DeVarney, Eric Greenberg, Matthew C. McMurdo, and David Natan resigned from Titan Pharmaceuticals. |
| 2024-04 | Seow Gim Shen assumed the position of Chief Executive Officer of Titan Pharmaceuticals. |
| 2024-05 | TalenTec's agreement with a local life insurance company for software support services and maintenance commenced for a one-year term. |
| 2024-07-11 | Black Titan Corporation was incorporated in the Cayman Islands. |
| 2024-08-19 | Titan Pharmaceuticals entered into a Merger and Contribution and Share Exchange Agreement with TalenTec Sdn. Bhd. and Black Titan Corporation. |
| 2024-08-29 | TalenTec entered into a lease with Boustead Nucleus Sdn Bhd. |
| 2024-09-26 | TalenTec changed its name from KE Sdn. Bhd. to TalenTec Sdn. Bhd. |
| 2024-10-02 | Black Titan Corporation confidentially filed a joint proxy statement/prospectus with the SEC. |
| 2024-10-24 | Seow Gim Shen resigned as Chief Executive Officer and Chairman of the Board of Titan Pharmaceuticals. |
| 2024-11-06 | Brynner Chiam was appointed as acting principal executive officer and acting principal financial officer of Titan Pharmaceuticals. |
| 2024-12-02 | Mr. Chay Weei Jye was appointed as Chief Executive Officer of Titan Pharmaceuticals. |
| 2025-01-03 | Titan Pharmaceuticals received a notice from Nasdaq regarding noncompliance with Listing Rule 5620 (failure to hold annual shareholder meeting). |
| 2025-01 | TalenTec engaged Mordor Intelligence to provide market information. |
| 2025-01 | TalenTec embarked on a strategy to introduce and market cloud-based solutions. |
| 2025-02-19 | TalenTec agreed to certain revisions in its credit facility agreement with Alliance Bank Malaysia Berhad. |
| 2025-03-20 | Titan Pharmaceuticals entered into an Employment Agreement with Chay Weei Jye. |
| 2025-03-26 | Titan Pharmaceuticals received a notice from Nasdaq regarding noncompliance with Listing Rule 5550(b)(1) (stockholders equity requirement). |
| 2025-03-27 | Gabriel Loh was appointed as an independent director of Titan Pharmaceuticals. |
| 2025-03-29 | Titan Pharmaceuticals entered into a Securities Purchase Agreement with Blue Harbor Asset Management L.L.C-FZ for $1.0 million in Series B Preferred Stock. |
| 2025-04-11 | Titan Pharmaceuticals completed the private placement transaction with Blue Harbor. |
| 2025-04-12 | The current term of TalenTec's PeopleSoft agreement expires. |
| 2025-05-13 | Titan Pharmaceuticals received a Notice of Conversion from Sire to convert Series AA Preferred Stock into common stock. |
| 2025-05-13 | Titan Pharmaceuticals received a Notice of Conversion from Blue Harbor to convert Series B Preferred Stock into common stock. |
| 2025-05-30 | Titan Pharmaceuticals issued 150,087 shares of common stock to Sire upon conversion. |
| 2025-05-30 | Titan Pharmaceuticals issued 265,913 shares of common stock to Blue Harbor upon conversion. |
| 2025-06-16 | Titan Pharmaceuticals conducted its 2025 Annual Meeting of Stockholders. |
| 2025-06-20 | Black Titan Corporation entered into a subscription agreement with ARC Group Limited for the purchase of up to $4,000,000 of Series A convertible preferred shares. |
| 2025-06-20 | Titan Pharmaceuticals received a notice from Nasdaq that it had regained compliance with the annual meeting requirement. |
| 2025-06-24 | Titan Pharmaceuticals completed an additional private placement with Blue Harbor for $600,000 in Series C Convertible Preferred Stock. |
| 2025-07-21 | The SEC declared the Form F-4 effective for the merger. |
| 2025-07-22 | Titan Pharmaceuticals filed a definitive proxy statement for a special meeting of stockholders to approve the merger. |
| 2025-07-25 | Share Exchange Agreement was dated. |
| 2025-08-21 | The SPA with ARC Group Limited was amended to increase the amount of Series A Preferred Shares to be purchased to up to $6,000,000. |
| 2025-08-22 | Titan Pharmaceuticals received a Notice of Conversion from Blue Harbor to convert Series B Preferred Stock into common stock. |
| 2025-08-22 | Titan Pharmaceuticals issued 67,420 shares of common stock to Blue Harbor upon conversion. |
| 2025-08-26 | The Merger Agreement was approved by Titan Pharmaceuticals' stockholders and TalenTec's stockholders. |
| 2025-09-17 | Titan Pharmaceuticals received a letter from Nasdaq confirming compliance with the Equity Rule. |
| 2025-10-01 | Black Titan Corporation consummated the acquisition of Titan Pharmaceuticals Inc. and TalenTec Sdn. Bhd. |
| 2025-10-01 | Black Titan submitted a Drawdown Notice for $5,500,000, resulting in the issuance of 5,500 Series A Preferred Shares to ARC Group Limited. |
| 2025-10-01 | Registration Rights Agreement was dated. |
| 2025-10-02 | Black Titan's ordinary shares began trading on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. |
| 2025-10-06 | Black Titan announced plans to seek long-term strategic crypto initiatives. |
| 2025-10-30 | Black Titan entered into a Settlement Agreement with Armistice Capital Master Fund Ltd. and repurchased warrants. |
| 2025-11-10 | Shang Ju (Czhang) Lin began serving as Co-Chief Executive Officer of Black Titan Corporation. |
| 2025-11-28 | Date of this Annual Report on Form 20-F. |
Recommendation
holdThe completion of the merger and the Nasdaq listing are significant milestones, providing the company with a public platform and access to capital. TalenTec, the core operating entity, demonstrates strong revenue and net income growth, driven by increasing demand for HCM solutions and a successful shift towards cloud-based offerings. The strategic initiatives for regional expansion and new product development are promising, aligning with favorable industry trends. However, the company faces substantial risks, including heavy reliance on a few key customers and third-party vendors, intense competition, and the inherent challenges of international expansion. Black Titan's pre-merger financial instability, though addressed by the merger and capital raise, introduces a layer of caution. The new crypto strategy adds an unquantified element of risk and potential reward. Given the mix of strong operational performance from TalenTec and the significant, yet manageable, risks and uncertainties associated with the new public entity and its ambitious growth plans, a 'hold' recommendation is appropriate. Investors should monitor the execution of growth strategies, integration of the merged entities, and the performance of the new crypto initiatives.
Keywords
Human Capital Management, HCM Solutions, SEC Filing, Merger, TalenTec, Black Titan Corporation, Nasdaq, Financial Performance, Cloud Solutions, SaaS, Oracle PeopleSoft, Dayforce HCM, SunFish Workplaze HR, MiHCM Cloud, Malaysia, Singapore, Indonesia, Philippines, Cryptocurrency, Digitalization, AI, Risk Factors, Capital Raise, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.